Publications
Publications
- January 2018
- HBS Case Collection
BeiGene Supplemental PowerPoint
By: Willy C. Shih and Jimmy Zhang
Abstract
BeiGene was a biopharmaceutical company founded on exploiting a temporal regulatory policy discontinuity. Because of regulatory challenges in China, most innovative new drugs launched there four to six years after their initial U.S. launches. This gave BeiGene a window of opportunity to develop drug candidates toward known targets with known mechanisms of actions that would allow it to become first-in-class in China. But how well would the company's strategy hold up to the 2017 regulatory reforms?
Keywords
Biotechnology; Pharmaceutical Company; Pharmaceuticals; China; Regulatory Environment; Business Strategy; Innovation Strategy; Situation or Environment; Pharmaceutical Industry; Biotechnology Industry; China
Citation
Shih, Willy C., and Jimmy Zhang. "BeiGene Supplemental PowerPoint." Harvard Business School PowerPoint Supplement 618-043, January 2018.